Core Insights - Monro Muffler Brake (MNRO) reported a quarterly loss of $0.09 per share, matching the Zacks Consensus Estimate, and a significant decline from earnings of $0.21 per share a year ago, resulting in an earnings surprise of -200% [1] - The company generated revenues of $294.99 million for the quarter ended March 2025, slightly exceeding the Zacks Consensus Estimate by 0.09%, but down from $310.08 million in the same quarter last year [2] - Monro shares have decreased by approximately 48.5% year-to-date, contrasting with a 0.7% gain in the S&P 500 [3] Earnings Outlook - The future performance of Monro's stock will largely depend on management's commentary during the earnings call and the company's earnings outlook, including current consensus earnings expectations for upcoming quarters [4][6] - The current consensus EPS estimate for the next quarter is $0.24 on revenues of $301.2 million, and for the current fiscal year, it is $0.87 on revenues of $1.24 billion [7] Industry Context - The Consumer Services - Miscellaneous industry, to which Monro belongs, is currently ranked in the top 37% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8]

Core Viewpoint - ePlus reported quarterly earnings of $1.11 per share, exceeding the Zacks Consensus Estimate of $0.87 per share, marking a 27.59% earnings surprise [1]. Financial Performance - The company posted revenues of $498.11 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 4.91% and down from $554.46 million year-over-year [2]. - Over the last four quarters, ePlus has surpassed consensus EPS estimates only once [2]. Stock Performance - ePlus shares have declined approximately 11.5% since the beginning of the year, contrasting with the S&P 500's decline of -0.6% [3]. - The current Zacks Rank for ePlus is 4 (Sell), indicating expected underperformance in the near future [6]. Earnings Outlook - The consensus EPS estimate for the upcoming quarter is $1.01 on revenues of $527.4 million, and for the current fiscal year, it is $4.61 on revenues of $2.17 billion [7]. - The trend for estimate revisions ahead of the earnings release was unfavorable, which may impact future stock performance [6]. Industry Context - The Business - Software Services industry, to which ePlus belongs, is currently in the top 9% of over 250 Zacks industries, suggesting a favorable industry outlook [8].

分组1 - Snowflake Inc. reported quarterly earnings of $0.24 per share, exceeding the Zacks Consensus Estimate of $0.22 per share, and showing an increase from $0.14 per share a year ago, representing an earnings surprise of 9.09% [1] - The company achieved revenues of $1.04 billion for the quarter ended April 2025, surpassing the Zacks Consensus Estimate by 3.74%, and up from $828.71 million in the same quarter last year [2] - Snowflake has consistently outperformed consensus EPS and revenue estimates over the last four quarters, indicating strong financial performance [2] 分组2 - The stock has gained approximately 18.4% since the beginning of the year, significantly outperforming the S&P 500's gain of 1% [3] - The current consensus EPS estimate for the upcoming quarter is $0.26 on revenues of $1.06 billion, and for the current fiscal year, it is $1.15 on revenues of $4.44 billion [7] - The Internet - Software industry, to which Snowflake belongs, is currently ranked in the top 26% of over 250 Zacks industries, suggesting a favorable outlook for the sector [8]

Core Viewpoint - Canada Goose reported quarterly earnings of $0.23 per share, exceeding the Zacks Consensus Estimate of $0.16 per share, and showing an increase from $0.14 per share a year ago, representing an earnings surprise of 43.75% [1][2] Financial Performance - The company posted revenues of $267.9 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 1.92%, and compared to $265.56 million in the same quarter last year [2] - Over the last four quarters, Canada Goose has consistently surpassed consensus EPS estimates and revenue estimates [2] Stock Performance - Canada Goose shares have declined approximately 11.1% since the beginning of the year, while the S&P 500 has gained 1% [3] - The stock's immediate price movement will largely depend on management's commentary during the earnings call [3] Future Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.59 on revenues of $67.14 million, and for the current fiscal year, it is $0.86 on revenues of $978.95 million [7] - The estimate revisions trend for Canada Goose is currently favorable, leading to a Zacks Rank 2 (Buy) for the stock, indicating expected outperformance in the near future [6] Industry Context - The Retail - Apparel and Shoes industry, to which Canada Goose belongs, is currently ranked in the bottom 47% of over 250 Zacks industries, suggesting potential challenges ahead [8]

Core Viewpoint - ViaSat reported a quarterly loss of $0.02 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.03, marking an earnings surprise of -166.67% [1] - The company has shown mixed performance in surpassing consensus EPS estimates over the last four quarters, achieving this only once [2] Financial Performance - ViaSat posted revenues of $1.15 billion for the quarter ended March 2025, which met the year-ago revenues and surpassed the Zacks Consensus Estimate by 1.18% [2] - The company has exceeded consensus revenue estimates three times in the last four quarters [2] Stock Performance - ViaSat shares have increased approximately 25.9% since the beginning of the year, significantly outperforming the S&P 500's gain of 1.4% [3] Future Outlook - The company's earnings outlook will be crucial for determining the sustainability of its stock price movement, with current consensus EPS estimates at $0.20 for the coming quarter and $0.28 for the current fiscal year [4][7] - The estimate revisions trend for ViaSat is currently mixed, resulting in a Zacks Rank 3 (Hold), indicating expected performance in line with the market [6] Industry Context - The Wireless Equipment industry, to which ViaSat belongs, is currently ranked in the top 8% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8]

Group 1 - Agilysys reported quarterly earnings of $0.54 per share, exceeding the Zacks Consensus Estimate of $0.26 per share, and showing an increase from $0.32 per share a year ago, resulting in an earnings surprise of 107.69% [1] - The company achieved revenues of $74.27 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 4.20%, and up from $62.22 million year-over-year [2] - Agilysys has outperformed consensus EPS estimates in all four of the last quarters [2] Group 2 - The stock has underperformed the market, losing approximately 34.7% since the beginning of the year, while the S&P 500 has gained 1.3% [3] - The current consensus EPS estimate for the upcoming quarter is $0.37 on revenues of $73.98 million, and for the current fiscal year, it is $1.63 on revenues of $317.63 million [7] - The Computer - Integrated Systems industry, to which Agilysys belongs, is currently ranked in the top 39% of over 250 Zacks industries, indicating a favorable industry outlook [8]

Core Viewpoint - Karyopharm Therapeutics (KPTI) shows significant upside potential with a mean price target of $33.07, indicating a 521.6% increase from its current price of $5.32 [1] Price Targets and Analyst Consensus - The average price target consists of seven estimates ranging from $8 to $67.47, with a standard deviation of $23.37, suggesting a high variability in analyst predictions [2] - The lowest estimate indicates a potential increase of 50.4%, while the highest suggests an upside of 1168.2% [2] - A low standard deviation among price targets indicates strong agreement among analysts regarding the stock's price movement direction [9] Earnings Estimates and Analyst Optimism - Analysts exhibit strong agreement in revising KPTI's earnings estimates higher, which correlates with potential stock price increases [4][11] - Over the past 30 days, one estimate has increased, leading to a 4.9% rise in the Zacks Consensus Estimate for the current year [12] - KPTI holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors [13] Caution on Price Targets - While price targets are commonly referenced, they can mislead investors, as empirical research shows they rarely indicate actual stock price movements [7][10] - Analysts may set overly optimistic price targets due to business incentives, which can inflate expectations [8]

分组1 - Flexible Solutions International Inc. (FSI) reported a quarterly loss of $0.02 per share, missing the Zacks Consensus Estimate of $0.05, and compared to earnings of $0.04 per share a year ago, representing an earnings surprise of -140% [1] - The company posted revenues of $7.47 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 26.73%, and down from year-ago revenues of $9.23 million [2] - Over the last four quarters, FSI has surpassed consensus EPS estimates just once and topped consensus revenue estimates only once [2] 分组2 - The stock has gained approximately 19.9% since the beginning of the year, outperforming the S&P 500's gain of 0.2% [3] - The current consensus EPS estimate for the coming quarter is $0.07 on revenues of $11.61 million, and for the current fiscal year, it is $0.30 on revenues of $48.78 million [7] - The Zacks Industry Rank for Chemical - Specialty is currently in the bottom 42% of over 250 Zacks industries, indicating potential underperformance compared to the top 50% of ranked industries [8]

Company Performance - Vivos Therapeutics, Inc. reported a quarterly loss of $0.45 per share, slightly worse than the Zacks Consensus Estimate of a loss of $0.44, and an improvement from a loss of $1.63 per share a year ago [1] - The company posted revenues of $3.02 million for the quarter, missing the Zacks Consensus Estimate by 18.49%, and down from $3.42 million in the same quarter last year [2] - Over the last four quarters, Vivos Therapeutics has surpassed consensus EPS estimates two times, but has not beaten consensus revenue estimates [2] Stock Performance - Vivos Therapeutics shares have declined approximately 29.1% since the beginning of the year, contrasting with the S&P 500's gain of 0.2% [3] - The current Zacks Rank for Vivos Therapeutics is 5 (Strong Sell), indicating expectations for the stock to underperform the market in the near future [6] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.39 on revenues of $4.2 million, and for the current fiscal year, it is -$1.54 on revenues of $16.6 million [7] - The trend for estimate revisions ahead of the earnings release has been unfavorable, which may impact future stock performance [6] Industry Context - The Medical - Drugs industry, to which Vivos Therapeutics belongs, is currently ranked in the top 26% of over 250 Zacks industries, suggesting a relatively strong industry performance [8]

Cava Group (CAVA) came out with quarterly earnings of $0.22 per share, beating the Zacks Consensus Estimate of $0.14 per share. This compares to earnings of $0.12 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 57.14%. A quarter ago, it was expected that this Mediterranean restaurant chain would post earnings of $0.06 per share when it actually produced earnings of $0.05, delivering a surprise of -16.67%.Over the last four qua ...